Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeCil: Cilengitide vs Cetuximab in Glioblastoma
NCT01044225Phase 2Terminated
- Sponsor
- Bart Neyns
- Start
- Sep 2009
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cilengitide, KL-140 in glioblastoma (GBM), sponsored by Bart Neyns. Started Sep 2009; status: terminated.
02
Drugs
cilengitideKL-140
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01044225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01044225.